New drug duo aims to tame stubborn blood disorder
NCT ID NCT07234019
Summary
This study is for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets, raising the risk of bleeding. It compares a new two-drug combination (rituximab plus an anti-CD38 antibody) against the standard single drug (rituximab alone) in people whose ITP didn't improve or came back after initial steroid treatment. The goal is to see if the combination is more effective at raising and maintaining safe platelet counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Science and Blood Disease Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.